Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis

- Primary endpoint was not achieved –

- Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform -